LRMR

Larimar Therapeutics, Inc. (LRMR) | Rumor.io

Larimar Therapeutics

LRMR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,394

Bullish sentiment (50-day avg)100%

Price to earnings ratio-1.4

Market capitalization329.3M

Earnings per share-2.01

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-165.7M

Social

What share of all stock conversation is about LRMR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 9

The market believes Larimar Therapeutics, Inc. (LRMR) has a strong base of long-term holders who are not concerned with short-term fluctuations, and expect the stock to trade in the double digits once the drug is approved.
An insider purchase of 50K shares has helped boost the stock, and some investors think it may break the $3.8 resistance level, while others are speculating about potential partnership or acquisition talks.
Major upcoming catalysts for LRMR include the completion of the rolling Biologics License Application (BLA) submission in Q3-Q4 2026, the start of the global Phase 3 confirmatory trial in mid-2026, and FDA acceptance of the BLA in late 2026/early 2027.

Generated by AI

Sentiment

Of the messages about LRMR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	82.32% -4.93
Bearish	—	0% 0	0% 0	17.68% +4.93

Bullish· Feb 26

$LRMR is expected to see significant price movement, potentially up to 10-20x, due to a group of investors who have a history of buying and profiting from similar stocks.
The company's drug has been granted Breakthrough Therapy designation by the FDA, indicating a substantial improvement over existing treatments for a serious disease, and its valuation could be worth significantly more than Biogen's $7 billion acquisition of a competing drug.
With a potential U.S. launch in the first half of 2027 and analysts' bullish price target bumps, $LRMR is seen as a high-risk, high-reward biotech play with significant upside potential.

Bearish· Jun 29

The company's lead drug has a safety issue that will limit commercial sales.
The market's perception of the company is currently wrong, and it may continue to sell off.
The company's clinical data release has led to a significant decline in stock price due to a high discontinuation rate among patients.

Generated by AI

Topics

Of the messages about LRMR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	62.5%	86.49%	67.66%
Technical Analysis	—	0%	0%	18.61%
Analysts	—	37.5%	8.11%	7.67%
Controversies	—	0%	5.41%	0.19%
Earnings	—	0%	0%	1.73%
Macro	—	0%	0%	4.14%

Announcements· Jun 29

Larimar Therapeutics, Inc. ($LRMR) submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia.
The submission is based on positive open-label data showing sustained increases in frataxin levels and a stable safety profile for up to 2 years.
Larimar expects to submit the remaining modules of the BLA in the second half of 2026, with a target commercial launch for nomlabofusp set for mid-2027.

Technical Analysis· Feb 25

$LRMR has formed a bull flag, indicating a potential breakout soon.
The stock has been holding strength, with buyers engaged and higher lows, suggesting a bullish trend.
A failed breakout above the trendline signals a potential trap, with a short-term bearish bias expected, and a risk of a downside move.

Generated by AI

Community

Of the messages about LRMR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	62.3%	47.23%
Newcomers	—	0%	37.7%	52.77%

Regulars· Feb 24

The stock is considered a good risk-reward opportunity in small-cap biotech, with analysts' targets ranging from mid to high teens, and a possible turning point for the company.
The stock has shown strong momentum, with buyers resisting pullbacks, and a defined catalyst path ahead, including potential regulatory updates that could spark a move.
The Breakthrough Therapy Designation granted to Larimar's nomlabofusp program by the FDA has the potential to accelerate approval, with a BLA filing planned for June 2026.

Newcomers· Feb 24

The FDA granted Breakthrough Therapy Designation to Larimar Therapeutics' lead candidate, nomlabofusp, for Friedreich's ataxia, a rare genetic disorder.
The designation is expected to support Larimar Therapeutics' plans to drop its BLA in June 2026.
Larimar Therapeutics' shares surged 32.38% to $3.727 after the FDA's announcement, with the company's stock analysis indicating a potential pivot in the market.

Generated by AI

News

Larimar Therapeutics appoints John B. Harlow, Jr. as president and COO

15h agoInvesting.com

Larimar Therapeutics names John Harlow president and COO

15h agoInvesting.com

Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp

Detailed price information for Larimar Therapeutics Inc (LRMR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measuresHigh patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion

1mo agoYahoo Finance

A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN)

2mo agoSeeking Alpha

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics Inc. (NASDAQ:LRMR) is one of the 10 best stocks under $10 that could triple. On June 29, Larimar Therapeutics Inc. (NASDAQ:LRMR) filed the first module of its Biologics License Application (BLA) to the U.S. FDA to get its Nomlabofusp therapy approved on an accelerated basis. The company also plans to submit the other […]

2mo agoYahoo Finance

Also Discussed

Investors talking about LRMR also mention

#	Name	Attention
1	Design Therapeutics, Inc.DSGN	0%0
2	Lexeo Therapeutics, Inc. Common StockLXEO	0%+0
3	Eledon Pharmaceuticals, Inc.ELDN	0%0
4	MRUS - Merus N.V.	——
5	EFUT - VanEck Ethereum Strategy ETF	——
6	CMRX - Chimerix, Inc.	——
7	VRNT - Verint Systems Inc.	——
8	TELA Bio, Inc.TELA	0%0
9	NLTX - Neoleukin Therapeutics, Inc.	——
10	Rhythm Pharmaceuticals, Inc.RYTM	0%0

Larimar Therapeutics, Inc.

Healthcare
Biotechnology

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an emphasis on Friedreich’s ataxia. The company’s core program is nomlabofusp, a protein replacement therapy designed to deliver frataxin inside cells and address the underlying biology of this inherited disorder. Larimar’s work centers on its proprietary intracellular delivery platform, which is intended to support the development of additional therapies for rare conditions caused by missing or deficient proteins. The company operates as a focused research and development organization, advancing clinical programs and related manufacturing, development, and regulatory activities through external partners. Larimar Therapeutics is based in Bala Cynwyd, Pennsylvania, and plays a specialized role in the rare-disease biopharmaceutical market by pursuing targeted treatments for patients with limited therapeutic options.

Website

Location

Three Bala Plaza East

Bala Cynwyd, PA, 19004

United States

Social

What share of all stock conversation is about LRMR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 9

The market believes Larimar Therapeutics, Inc. (LRMR) has a strong base of long-term holders who are not concerned with short-term fluctuations, and expect the stock to trade in the double digits once the drug is approved.
An insider purchase of 50K shares has helped boost the stock, and some investors think it may break the $3.8 resistance level, while others are speculating about potential partnership or acquisition talks.
Major upcoming catalysts for LRMR include the completion of the rolling Biologics License Application (BLA) submission in Q3-Q4 2026, the start of the global Phase 3 confirmatory trial in mid-2026, and FDA acceptance of the BLA in late 2026/early 2027.

Generated by AI

Sentiment

Of the messages about LRMR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	82.32% -4.93
Bearish	—	0% 0	0% 0	17.68% +4.93

Bullish· Feb 26

$LRMR is expected to see significant price movement, potentially up to 10-20x, due to a group of investors who have a history of buying and profiting from similar stocks.
The company's drug has been granted Breakthrough Therapy designation by the FDA, indicating a substantial improvement over existing treatments for a serious disease, and its valuation could be worth significantly more than Biogen's $7 billion acquisition of a competing drug.
With a potential U.S. launch in the first half of 2027 and analysts' bullish price target bumps, $LRMR is seen as a high-risk, high-reward biotech play with significant upside potential.

Bearish· Jun 29

The company's lead drug has a safety issue that will limit commercial sales.
The market's perception of the company is currently wrong, and it may continue to sell off.
The company's clinical data release has led to a significant decline in stock price due to a high discontinuation rate among patients.

Generated by AI

Topics

Of the messages about LRMR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	62.5%	86.49%	67.66%
Technical Analysis	—	0%	0%	18.61%
Analysts	—	37.5%	8.11%	7.67%
Controversies	—	0%	5.41%	0.19%
Earnings	—	0%	0%	1.73%
Macro	—	0%	0%	4.14%

Announcements· Jun 29

Larimar Therapeutics, Inc. ($LRMR) submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia.
The submission is based on positive open-label data showing sustained increases in frataxin levels and a stable safety profile for up to 2 years.
Larimar expects to submit the remaining modules of the BLA in the second half of 2026, with a target commercial launch for nomlabofusp set for mid-2027.

Technical Analysis· Feb 25

$LRMR has formed a bull flag, indicating a potential breakout soon.
The stock has been holding strength, with buyers engaged and higher lows, suggesting a bullish trend.
A failed breakout above the trendline signals a potential trap, with a short-term bearish bias expected, and a risk of a downside move.

Generated by AI

Community

Of the messages about LRMR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	62.3%	47.23%
Newcomers	—	0%	37.7%	52.77%

Regulars· Feb 24

The stock is considered a good risk-reward opportunity in small-cap biotech, with analysts' targets ranging from mid to high teens, and a possible turning point for the company.
The stock has shown strong momentum, with buyers resisting pullbacks, and a defined catalyst path ahead, including potential regulatory updates that could spark a move.
The Breakthrough Therapy Designation granted to Larimar's nomlabofusp program by the FDA has the potential to accelerate approval, with a BLA filing planned for June 2026.

Newcomers· Feb 24

The FDA granted Breakthrough Therapy Designation to Larimar Therapeutics' lead candidate, nomlabofusp, for Friedreich's ataxia, a rare genetic disorder.
The designation is expected to support Larimar Therapeutics' plans to drop its BLA in June 2026.
Larimar Therapeutics' shares surged 32.38% to $3.727 after the FDA's announcement, with the company's stock analysis indicating a potential pivot in the market.

Generated by AI

Larimar Therapeutics

Social

Jul 9

Bullish· Feb 26

Bearish· Jun 29

Announcements· Jun 29

Technical Analysis· Feb 25

Regulars· Feb 24

Newcomers· Feb 24

Larimar Therapeutics appoints John B. Harlow, Jr. as president and COO

Larimar Therapeutics names John Harlow president and COO

Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN)

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Also Discussed

Larimar Therapeutics, Inc.

Company Information

Location

Larimar Therapeutics appoints John B. Harlow, Jr. as president and COO

Larimar Therapeutics names John Harlow president and COO

Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN)

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Also Discussed

Social

Jul 9

Bullish· Feb 26

Bearish· Jun 29

Announcements· Jun 29

Technical Analysis· Feb 25

Regulars· Feb 24

Newcomers· Feb 24